Effectiveness and Safety of Short-Course Chemotherapy Regimens for Drug-Resistant Tuberculosis: Literature Review and Meta-Analysis
https://doi.org/10.58838/2075-1230-2025-103-2-26-37
Abstract
The objective: to evaluate clinical effectiveness and safety of short-course chemotherapy regimens in patients with drug-resistant tuberculosis based on a systematic and meta-analytic study.
Subjects and Methods. A systematic search for scientific publications published between 01.01.2018 and 01.10.2023 was conducted in PubMed and eLibrary. Sixty-six studies were selected using the keywords “treatment of drug-resistant tuberculosis, randomized clinical trials”. By a manual review, 7 publications meeting required parameters for meta-analysis were identified.
Results. A single-group meta-analysis of the effectiveness of short-term chemotherapy regimens demonstrated the following: a favorable outcome can be achieved in 80.9% of cases; an unfavorable outcome occurs in 19.4%; sputum culture conversion by 8 weeks of chemotherapy is achieved in 74.6% of cases; SAEs were registered in 15.1% of patients, grade 3 and higher SAEs- in 39.5% (based on 4 publications).
About the Authors
A. V. Abramchenko
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Anna V. Abramchenko - Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections, Assistant of Phthisiology Department, Pirogov Russian National Research Medical University
4 Build. 2 Dostoevsky St., Moscow, 127473
Phone:+7 (495) 631-15-15
M. I. Romanova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Maria I. Romanova - Junior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections
4 Build. 2 Dostoevsky St., Moscow, 127473
Phone:+7 (495) 631-15-15
A. I. Gayda
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Anastasiya I. Gayda - Candidate of Medical Sciences, Senior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections
4 Build. 2 Dostoevsky St., Moscow, 127473
Phone:+7 (495) 631-15-15
G. N. Mozhokina
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Galina N. Mozhokina - Doctor of Medical Sciences, Leading Researcher of Laboratory of Immunopathology and Immunodiagnostics of Tuberculosis Infection
4 Build. 2 Dostoevsky St., Moscow, 127473
Phone:+7 (495) 631-15-15
A. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Anastasiya G. Samoylova -Doctor of Medical Sciences, Deputy Director for Research
4 Build. 2 Dostoevsky St., Moscow, 127473
Phone:+7 (495) 631-15-15
I. A. Vasilyeva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Irina A. Vasilyeva - Doctor of Medical Sciences, Professor, Director, Head of Phthisiology Department, Pirogov Russian National Research Medical University
4 Build. 2 Dostoevsky St., Moscow, 127473
Phone:+7 (495) 631-15-15
References
1. Maryandyshev A.O., Kulizhskaya A.I., Khimova E.S., Perkhin D.V., Sveshnikova O.M., Presnova S.E., Kurochkina N.P., Sotnikov A.S., Lescheva N.A., Vasilyeva I.A. Short course treatment regimens for multiple drug resistant tuberculosis in Arkhangelsk, Murmansk and Belgorod Regions. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 7, pp. 5-10. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-7-5-10
2. Bhering M., Kritski A., Nunes C., Duarte R. Multidrug-resistant tuberculosis in Lisbon: unfavourable treatment and associated factors, 2000–2014. The International Journal Tuberculosis and Lung Diseases, 2019, vol. 23, no. 10, pp. 1075-1081. https://doi.org/10.5588/ijtld.18.0596
3. Bull World Health Organ., 2014, vol. 92, no. 1-6. Available: https://docs.yandex.ru/docs/view?tm=1744394614&tld=ru&lang=ru&name=byulleten%27_voz_vypusk_92_nomera1_62014.rus.pdf&text=Bull%20World%20Health%20Organ%202014%3B%2092%3A68%E2%80%9374&url=https%3A%2F%2F Ассessed December 12, 2024
4. Common Terminology Criteria for Adverse Events (CTCAE), v5.0 Publish Date: November 27, 2017. Available: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf Ассessed December 12, 2024
5. Conradie F., Bagdasaryan T.R., Borisov S., Howell P., Mikiashvili L., Ngubane N., Samoilova A., Skornykova S., Tudor E., Variava E., Yablonskiy P., Everitt D., Wills G.H., Sun E., Olugbosi M., Egizi E., Li M., Holsta A., Timm J., Bateson A., Crook A.M., Fabiane S.M., Hunt R., McHugh T.D., Tweed C.D., Foraida S., Mendel C.M., Spigelman M. Bedaquiline-pretomanid-linezoli d regimens for drug-resistant tuberculosis. N. Engl. J. Med., 2022, no. 387, pp. 810-823.
6. Conradie F., Diacon A.H., Ngubane N., Howell P., Everitt D., Crook A.M., Mendel C.M., Egizi E., Moreira J., Timm J., McHugh T.D., Wills G.H., Bateson A., Hunt R., Van Niekerk C., Li M., Olugbosi M., Spigelman M. Treatment of highly drug-resistant pulmonary tuberculosis. N. Engl. J. Med., 2020, no. 382, pp. 893-902.
7. Du Y., Qiu C., Chen X., Wang J., Jing W., Pan H., Chen W., Liu Y., Li C., Xi X., Yin H., Zeng J., Zhang X., Xu T., Wang Q., Guo R., Wang J., Pang Y., Chu N. Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in China. Clin. Infect. Dis., 2020, no. 71, pp. 1047-1054.
8. Esmail A., Oelofse S., Lombard C., Perumal R., Mbuthini L., Goolam Mahomed A., Variava E., Black J., Oluboyo P., Gwentshu N., Ngam E., Ackerman T., Marais L., Mottay L., Meier S., Pooran A., Tomasicchio M., Te Riele J., Derendinger B., Ndjeka N., Maartens G., Warren R., Martinson N., Dheda K. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am. J. Respir. Crit. Care Med., 2022, no. 205, pp. 1214-1227.
9. Global Programme on Tuberculosis and Lung Health (GTB) 2023. Target regimen profiles for tuberculosis treatment, 2023 update. Geneva, World Health Organization, 2023. License: CC BY-NC-SA 3.0 IGO
10. Global tuberculosis report 2024. Geneva, World Health Organization, 2024. License: CC BY-NC-SA 3.0 IGO.
11. Goodall R.L., Meredith S.K., Nunn A.J., Bayissa A., Bhatnagar A.K., Bronson G., Chiang C.Y., Conradie F., Gurumurthy M., Kirenga B., Kiria N., Meressa D., Moodliar R., Narendran G., Ngubane N., Rassool M., Sanders K., Solanki R., Squire S.B., Torrea G., Tsogt B., Tudor E., Van Deun A., Rusen I.D. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet, 2022, no. 400, pp. 1858-1868.
12. Kuaban C., Noeske J., Rieder H.L., Aït-Khaled N., Abena Foe J.L., Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int. J. Tuberc. Lung Dis., 2015, no. 19, pp. 517-524.
13. Kyaw S.L. Loss to follow-up (LTFU) during tuberculosis treatment. http://doi.org/10.5772/intechopen.81900. In: Healthcare Access–Regional Overviews [Working Title]. IntechOpen, 2019.
14. Mok J., Lee M., Kim D.K., Kim J.S., Jhun B.W., Jo K.W., Jeon D., Lee T., Lee J.Y., Park J.S., Lee S.H., Kang Y.A., Lee J.K., Kwak N., Ahn J.H., Shim T.S., Kim S.Y., Kim S., Kim K., Seok K.H., Yoon S., Kim Y.R., Kim J., Yim D., Hahn S., Cho S.N., Yim J.J. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet, 2022, no. 400, pp. 1522-1530.
15. Namukwaya E., Nakwagala F.N., Mulekya F., Mayanja-Kizza H., Mugerwa R. Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda. Afr. Health Sci., 2011, no. 11, suppl. 1, pp. S105-111.
16. Nunn A.J., Phillips P.P.J., Meredith S.K., Chiang C.Y., Conradie F., Dalai D., van Deun A., Dat P.T., Lan N., Master I., Mebrahtu T., Meressa D., Moodliar R., Ngubane N., Sanders K., Squire S.B., Torrea G., Tsogt B., Rusen I.D. A trial of a shorter regimen for rifampin-resistant tuberculosis. N. Engl. J. Med., 2019, no. 380, pp. 1201-1213.
17. Nyang'wa B.T., Berry C., Kazounis E., Motta I., Parpieva N., Tigay Z., Solodovnikova V., Liverko I., Moodliar R., Dodd M., Ngubane N., Rassool M., McHugh T.D., Spigelman M., Moore D.A.J., Ritmeijer K., du Cros P., Fielding K. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med., 2022, no. 387, pp. 2331-2343.
18. Piubello A., Harouna S.H., Souleymane M.B., Boukary I., Morou S., Daouda M., Hanki Y., Van Deun A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int. J. Tuberc. Lung Dis., 2014, no. 18, pp. 1188-1194.
19. Prasad R., Singh A., Gupta N. Adverse drug reactions with first-line and second-line drugs in treatment of tuberculosis. Annals of the National Academy of Medical Sciences (India), 2021, no. 57, pp. 16-35. http://doi.org/10.1055/s-0040-1722535
20. Van Deun A., Maug A.K., Salim M.A., Das P.K., Sarker M.R., Daru P., Rieder H.L. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med., 2010, no. 182, pp. 684-692.
21. WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva, World Health Organization, 2022. License: CC BY-NC-SA 3.0IGO.
22. WHO, Key updates to the treatment of drug-resistant tuberculosis, June 2024.
23. World Health Organization. Global Tuberculosis Report; WHO/HTM/TB/2012.6; WHO, Geneva, Switzerland, 2012.
24. Yang Q., Han J., Shen J., Peng X., Zhou L., Yin X. Diagnosis and treatment of tuberculosis in adults with HIV. Medicine (Baltimore), 2022, vol. 101, no. 35, pp. e30405. https://doi.org/10.1097/MD.0000000000030405
Review
For citations:
Abramchenko A.V., Romanova M.I., Gayda A.I., Mozhokina G.N., Samoylova A.G., Vasilyeva I.A. Effectiveness and Safety of Short-Course Chemotherapy Regimens for Drug-Resistant Tuberculosis: Literature Review and Meta-Analysis. Tuberculosis and Lung Diseases. 2025;103(2):26-37. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-2-26-37
Views:
234
Email this article 